Recombinant LH in ovarian stimulation

Reprod Biomed Online. 2005 Jun;10(6):774-85. doi: 10.1016/s1472-6483(10)61123-6.

Abstract

The advent of recombinant gonadotrophins brought significant changes in fertility therapy. Treatment options with recombinant gonadotrophins add more to knowledge on folliculogenesis and ovarian steroidogenesis. Over a decade, recombinant LH (rLH) has been used for clinical trials, and the amount of peripheral LH that is necessary for optimal follicular growth, oocyte maturation, subsequent embryo development and assisted reproduction outcome during ovulation induction can now be better evaluated. This review evaluates the effect of rLH supplementation on ovarian stimulation and assisted reproduction outcome. The studies conducted with rLH supplementation in ovarian stimulation in different groups of patients and in cases of controlled ovarian stimulation are clearly discussed in this review.

Publication types

  • Review

MeSH terms

  • Female
  • Follicle Stimulating Hormone / therapeutic use
  • Gonadotropin-Releasing Hormone / agonists
  • Gonadotropin-Releasing Hormone / antagonists & inhibitors
  • Gonadotropins / metabolism
  • Gonadotropins / pharmacology
  • Humans
  • Hypogonadism / drug therapy
  • Infertility, Female / drug therapy*
  • Infertility, Female / etiology
  • Luteinizing Hormone / pharmacology
  • Luteinizing Hormone / therapeutic use*
  • Maternal Age
  • Ovarian Follicle / drug effects
  • Ovarian Follicle / physiology
  • Ovulation Induction / methods*
  • Polycystic Ovary Syndrome / complications
  • Polycystic Ovary Syndrome / drug therapy
  • Pregnancy
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / therapeutic use
  • Reproductive Techniques, Assisted

Substances

  • Gonadotropins
  • Recombinant Proteins
  • Gonadotropin-Releasing Hormone
  • Luteinizing Hormone
  • Follicle Stimulating Hormone